Compounded GLP-1s are no longer to be sold following the FDA announcement that the shortage of semaglutide and tirzepatide ended.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

The researchers found that after 64 weeks, participants had a mean weight loss of −16.7%, with a mean semaglutide dose of 1.08mg/week.

It included a woman in her 50s who went temporarily blind in one eye a day after injecting her first semaglutide dose. After stopping the medication, her sight returned two months later.

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts. Export articles to Mendeley Get article recommendations from ACS based on references in your ...

Average weight loss reached 16.7% after 64 weeks’ use of the digital health platform, which combines tailored semaglutide dosing with intensive behavioral therapy delivered via an app.

The research focused on four patients who developed this symptom after their semaglutide dose was increased. In each case, the reaction was rated as “probable” using the Naranjo scale, a tool used by ...

Notably, the enobosarm 3mg + semaglutide was the best dose with a >99% mean relative reduction in loss of lean mass (p <0.001). Enobosarm 6mg + semaglutide dose was not better than the Enobosarm ...